How to Buy Tvardi Therapeutics Stock
Tvardi Therapeutics Inc
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Tvardi Therapeutics stock last closed at $23.79, up 0.88% from the previous day, and has increased 105.13% in one year. It has overperformed other stocks in the Biotechnology industry by 1.69 percentage points. Tvardi Therapeutics stock is currently +192.8% from its 52-week low of $8.13, and -30.66% from its 52-week high of $34.31.
There are currently 9.38M shares of TVRD outstanding. The market value of TVRD is $223.09M. In the past 24 hours, 11,100 TVRD shares were traded.
How to Buy Tvardi Therapeutics Stock
Not sure how to invest in Tvardi Therapeutics stock? Here's how.
- Choose where to buy Tvardi Therapeutics stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you decide where to buy Tvardi Therapeutics stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Select your payment method and add your information.
- Evaluate Tvardi Therapeutics stock: The Tvardi Therapeutics ticker symbol is TVRD. Is Tvardi Therapeutics stock a good investment? Should you buy shares of TVRD? How do TVRD's underlying business fundamentals look? Do top analysts think Tvardi Therapeutics is a good buy? Why has TVRD's stock price moved recently? (Hint: Our stock research website can help you understand if TVRD is a good stock to buy).
- Make your TVRD buy order: Decide if you will purchase TVRD shares at the current market price or use a limit order to buy TVRD shares at a given price.
- Get key alerts regarding your TVRD position: Create a watchlist to track your position in Tvardi Therapeutics stock.
Step 1: Choose where to buy Tvardi Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy TVRD shares.
Our preferred brokerage: eToro
We believe that eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro has a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked the right brokerage, you'll need to fill out some personal details so you are able to invest in TVRD today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to open your new trading account.
- Send your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have created your account on the best app for stock investing, you need to deposit funds:
Watch the video below if you need help depositing funds into your new brokerage account.
Step 4: Evaluate Tvardi Therapeutics stock
After you have identified the best place to buy Tvardi Therapeutics stock, it's crucial to evaluate their stock before you buy, so you actually wrap your head around the risk as well as the opportunity.
Overview of key TVRD info
Tvardi Therapeutics Due Diligence Score
WallStreetZen was created to help average investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on TVRD's stock page.
What is the fair value of TVRD stock?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge TVRD's true value.
Using relative valuations metrics:
- TVRD may be overvalued based on its P/B ratio of 6.78x, relative to Biotechnology industry P/B ratio of 4.42x
You can do more valuation analysis on TVRD's stock here.
Is TVRD a healthy company?
Positive Financial Indicators:
- There are more short-term assets than short-term liabilities on the TVRD balance sheet.
- There are more short-term assets than long-term liabilities on the TVRD balance sheet.
- TVRD has cash burn of 31584000. It has sufficient cash and short-term investments to cover this for at least one year.
- TVRD has $40.99M in cash and short term investments. This is sufficient to cover its annual cash burn of $31.58M.
- TVRD has a low debt to equity ratio of 0.33.
Negative Financial Indicators:
- Total TVRD debt is higher than 5 years ago, relative to shareholder equity.
- TVRD profit margin has gone up by 6.62 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy Tvardi Therapeutics stock, according to analysts?
Out of 5 sell side analysts who give ratings on TVRD, the consensus analyst rating on Tvardi Therapeutics is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
You can dig deeper into what analysts are projecting on the Tvardi Therapeutics stock forecast page.
TVRD Technicals
How is TVRD performing as a company?
Last year, TVRD revenue was $6.58M. In the last 5 year, TVRD's revenue has grown by -22.82% per year. This was slower than the Biotechnology industry average of 63.37%.
You can analyze TVRD's earnings and revenue performance here.
Latest Insiders Trades at TVRD
In the last year, executives and large shareholders at TVRD have sold more shares than they have bought.
Christopher Posner, PRESIDENT AND CEO of TVRD, was the latest TVRD insider to sell. They sold $2,769.25 worth of TVRD stock on Feb 28, 2025.
Dig into more about who owns TVRD stock here.
Can I get consistent income from TVRD stock?
No, Tvardi Therapeutics doesn't provide an income stream by paying out dividends.
What do other investors have to say about TVRD?
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Make your TVRD buy order
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are mostly fine for most investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific price, place a limit order.
Click the Open button and your broker will execute your order.
If you want more help with investing in stocks on eToro, click the how to video below:
Step 6: Get key alerts regarding your TVRD position
Now that you own some TVRD shares, you'll want to keep up with your new company.
Create a watchlist to get notified of important updates regarding your TVRD stock.
TVRD Feed
How to Buy Stock in Tvardi Therapeutics
To reiterate, here are the 6 steps to buy Tvardi Therapeutics stock:
- Choose where to buy Tvardi Therapeutics stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Evaluate Tvardi Therapeutics stock
- Make your TVRD buy order
- Get key alerts regarding your TVRD position
If you need a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep an eye on your investment in Tvardi Therapeutics, add TVRD to your watchlist below.
More Content You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.